Literature DB >> 18199793

Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.

Yu-Tsung Huang1, Cheng-Hsiang Hsiao, Chun-Hsing Liao, Chung-Wei Lee, Po-Ren Hsueh.   

Abstract

We describe the development of nonsusceptibility to daptomycin and vancomycin during treatment for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia associated with infective endocarditis and probable septic thrombophlebitis in a uremic patient. MRSA bacteremia persisted during glycopeptide and subsequent daptomycin treatment but cleared after 5 days' treatment with linezolid and fusidic acid.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18199793      PMCID： PMC2268353          DOI： 10.1128/JCM.01844-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  18 in total

Review 1.  Mechanisms of action of newer antibiotics for Gram-positive pathogens.

Authors:  Robert Ew Hancock
Journal:  Lancet Infect Dis       Date:  2005-04       Impact factor: 25.071

2.  Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.

Authors:  Kathleen Julian; Klaudia Kosowska-Shick; Cynthia Whitener; Martin Roos; Harald Labischinski; Aileen Rubio; Leslie Parent; Lois Ednie; Laura Koeth; Tatiana Bogdanovich; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

3.  Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus.

Authors:  M K Hayden; K Rezai; R A Hayes; K Lolans; J P Quinn; R A Weinstein
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

Authors:  L Cui; H Murakami; K Kuwahara-Arai; H Hanaki; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  A Mangili; I Bica; D R Snydman; D H Hamer
Journal:  Clin Infect Dis       Date:  2005-02-17       Impact factor: 9.079

7.  Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.

Authors:  Francisco M Marty; Wendy W Yeh; Christine B Wennersten; Lata Venkataraman; Esperanza Albano; Edwin P Alyea; Howard S Gold; Lindsey R Baden; Satish K Pillai
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

Review 8.  Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.

Authors:  Judith N Steenbergen; Jeff Alder; Grace M Thorne; Francis P Tally
Journal:  J Antimicrob Chemother       Date:  2005-02-10       Impact factor: 5.790

9.  Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.

Authors:  Michael M Mwangi; Shang Wei Wu; Yanjiao Zhou; Krzysztof Sieradzki; Herminia de Lencastre; Paul Richardson; David Bruce; Edward Rubin; Eugene Myers; Eric D Siggia; Alexander Tomasz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

10.  Vancomycin heteroresistance in methicillin-resistant Staphylococcus aureus, Taiwan.

Authors:  Jiun-Ling Wang; Sung-Pin Tseng; Po-Ren Hsueh; Keiichi Hiramatsu
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883
View more
  9 in total

1.  Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.

Authors:  Kimberly C Claeys; Jordan R Smith; Anthony M Casapao; Ryan P Mynatt; Lisa Avery; Anjali Shroff; Deborah Yamamura; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

2.  Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus.

Authors:  Anu Daniel; Chad Euler; Mattias Collin; Peter Chahales; Kenneth J Gorelick; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 3.  Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Authors:  Mukesh Patel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 4.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

5.  Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  Ryan Yu; Suzanne E Dale; Deborah Yamamura; Vida Stankus; Christine Lee
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

6.  Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin.

Authors:  Beth White; R Andrew Seaton
Journal:  Infect Drug Resist       Date:  2011-05-24       Impact factor: 4.003

7.  Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.

Authors:  Kristina Nadrah; Franc Strle
Journal:  Chemother Res Pract       Date:  2011-04-18

8.  Single nucleotide polymorphism leads to daptomycin resistance causing amino acid substitution-T345I in MprF of clinically isolated MRSA strains.

Authors:  Masaki Nakamura; Hayato Kawada; Hiroki Uchida; Yusuke Takagi; Shuichi Obata; Ryotaro Eda; Hideaki Hanaki; Hidero Kitasato
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

9.  Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients.

Authors:  Chung-Chih Lai; Wang-Huei Sheng; Jann-Tay Wang; Aristine Cheng; Yu-Chung Chuang; Yee-Chun Chen; Shan-Chwen Chang
Journal:  BMC Infect Dis       Date:  2013-02-04       Impact factor: 3.090
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.